Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Associations between quantitative contrast sensitivity, optical coherence tomography and progression prognostication in intermediate age-related macular degeneration.
Author Affiliations & Notes
  • Cade F Bennett
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Francesco Romano
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Opthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Filippos Vingopoulos
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Opthalmology, Stanford University School of Medicine, Stanford, California, United States
  • Mauricio De Jesus Garcia
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Augustine Bannerman
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Xinyi Ding
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Opthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Dimitrios Ntentakis
    Opthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Isabella Stettler
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Ioanna Ploumi
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Katherine M Overbey
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Romy Bejjani
    Opthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Jocelyn Rodriguez
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Demetrios G. Vavvas
    Opthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Deeba Husain
    Opthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Joan W Miller
    Opthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • John B Miller
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Opthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Cade Bennett None; Francesco Romano None; Filippos Vingopoulos None; Mauricio Garcia None; Augustine Bannerman None; Xinyi Ding None; Dimitrios Ntentakis None; Isabella Stettler None; Ioanna Ploumi None; Katherine Overbey None; Romy Bejjani None; Jocelyn Rodriguez None; Demetrios Vavvas TwentyTwenty, Sumitomo/Sunovion, Cambridge Polymer Group, Olix Pharma, Valitor, Code C (Consultant/Contractor), National Eye Institute, NIH, Research to Prevent Blindness, Loefflers Family Foundation, Yeatts Family Foundation, Alcon Research Institute, Code F (Financial Support), Drusolv Therapeutics, Code O (Owner), Mass Eye and Ear, Code P (Patent), Olix Pharma, Valitor, Code S (non-remunerative); Deeba Husain Genentech, Allergan, Novartis, Omeicos Therapeutics, Code C (Consultant/Contractor), m NIH, National Eye Institute, Lions Vision Gift, Commonwealth Grant, Lions International, Syneos LLC, Macular Society, Code F (Financial Support); Joan Miller Sunovion, Genentech/Roche, KalVista Pharmaceuticals, Code C (Consultant/Contractor), Lowy Medical Research Institute, National Eye Institute, Heidelberg Engineering, Code F (Financial Support), Ciendias Bio, Code I (Personal Financial Interest), ONL Therapeutics, Valeant Pharmaceuticals/Mass. Eye and Ear, Drusolv Therapeutics, Code P (Patent), Aptinyx, Inc., Sunovion, KalVista Pharmaceuticals, ONL Therapeutics, Valeant Pharmaceuticals/Mass. Eye and Ear, Code R (Recipient), Aptinyx, Inc., ONL Therapeutics, Code S (non-remunerative); John Miller Alcon, Allergan, Carl Zeiss, Sunovion, Genentech, Topcon, Code C (Consultant/Contractor)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 2306. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Cade F Bennett, Francesco Romano, Filippos Vingopoulos, Mauricio De Jesus Garcia, Augustine Bannerman, Xinyi Ding, Dimitrios Ntentakis, Isabella Stettler, Ioanna Ploumi, Katherine M Overbey, Romy Bejjani, Jocelyn Rodriguez, Demetrios G. Vavvas, Deeba Husain, Joan W Miller, John B Miller; Associations between quantitative contrast sensitivity, optical coherence tomography and progression prognostication in intermediate age-related macular degeneration.. Invest. Ophthalmol. Vis. Sci. 2024;65(7):2306.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To assess the association between spectral domain optical coherence tomography (SD-OCT) biomarkers, quantitative contrast sensitivity function (qCSF) metrics and progression from intermediate to late age-related macular degeneration (AMD).

Methods : This retrospective, observational study included 205 eyes of 134 patients with (1) intermediate AMD as per Beckman classification, (2) same-day OCT and qCSF test, (3) visual acuity (VA) ≥20/200 Snellen, and (4) at least 24 months of follow-up. qCSF metrics included the area under the logCSF curve (AULCSF), contrast acuity (CA), and contrast sensitivity (CS) at 1-to-18 cycles per degree (cpd). OCT scans and charts were reviewed for cuticular drusen, subretinal drusenoid deposits (SDD), hyporeflective drusen cores (hDC), refractile drusen, number of hyperreflective foci (HRF) and development of wet AMD or complete RPE and outer retinal atrophy (cRORA). Outer nuclear layer (ONL) thickness and retinal pigment epithelium (RPE) volume were semi-automatically collected using the ETDRS grid.
Generalized linear mixed-effects models assessed the association between qCSF and OCT biomarkers. Cox regression evaluated the impact of qCSF and OCT on the progression to wet AMD and cRORA. All models were nested and adjusted for age and lens opacity.

Results : Median age was 73 years (69-78) with 63% females. Mixed-effects regression revealed higher RPE volume in the central subfield and more iHRF were significantly associated with reduced AULCSF, CA and CS at 6-12 cpd. Thinner ONL in the inner ring and a greater iHRF number were associated with reduced CS at 1 and 3 cpd.
During follow-up, 35 eyes developed wet AMD (17%) and 53 progressed to cRORA (26%).
Cox regression revealed SDD, thinner inner ring ONL and CS at 1.5 cpd were associated with wet AMD. Conversely, higher inner ring RPE volume, hDC, SDD, CS at 1 cpd and a greater number of iHRF were significantly associated with progression to cRORA.

Conclusions : This study provides more structure-function analysis of OCT and qCSF metrics in intermediate AMD. Central RPE volume, parafoveal ONL thinning and iHRF demonstrate the most robust associations of CS function. Various biomarkers and CS at low spatial frequencies were associated with late AMD progression, offering valuable parameters for stratifying intermediate AMD patients in clinical settings.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×